PARP1 and breast cancer: Considering that polytherapy presents several disadvantages (such as patient compliance reduction, risk of adverse drug interactions) over monotherapy, here we propose an in silico mixed ligand/structure-based design of the first-in-class CDK-1/PARP-1 dual inhibitors as anti-BC agents.